- ESTROGEN-RELATED RECEPTOR ALPHA (ERRα) MODULATORS
-
The present invention is directed to compounds according to Formula (I) and the pharmaceutically acceptable salts thereof. The compounds can be used as modulators of Estrogen-related Receptor alpha (ERRα) and have utility in the treatment of ERRα-mediated
- -
-
Page/Page column 59
(2021/01/23)
-
- MASP-2 INHIBITORS AND METHODS OF USE
-
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.
- -
-
Paragraph 1738-1740
(2019/12/24)
-
- Synthesis method of 2-methoxyl-4-cyanobenzaldehyde
-
The invention discloses a synthesis method of 2-methoxyl-4-cyanobenzaldehyde. The method comprises the following steps: 1, carrying out acylating chlorination on 4-methyl-3-methoxybenzoic acid servingas a raw material, and then carrying out aminolysis to
- -
-
-
- HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
-
The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical composi
- -
-
Page/Page column 177-178
(2015/11/09)
-
- ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
-
The present invention provides a compound of formula (I). Said compound is inhibitor of CYP11B2 and/or CYP11B1, and thus can be employed for the treatment of a disorder or disease mediated by CYP11B2 and/or CYP11B1.
- -
-
-
- Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-monocyclic arginine surrogates
-
Investigations on P2-P3-heterocyclic dipeptide surrogates directed towards identification of an orally bioavailable thrombin inhibitor led us to pursue novel classes of achiral, non-covalent P1-arginine derivatives. The design, synthesis, and biological activity of inhibitors NC1-NC30 that feature three classes of monocyclic P1-arginine surrogates will be disclosed: (1) (hetero)aromatic amidines, amines and hydroxyamidines, (2) 2-aminopyrazines, and (3) 2-aminopyrimidines and 2-aminotetrahydropyrimidines.
- Reiner, John E.,Siev, Daniel V.,Araldi, Gian-Luca,Cui, Jingrong Jean,Ho, Jonathan Z.,Reddy, Komandla Malla,Mamedova, Lala,Vu, Phong H.,Lee, Kuen-Shan S.,Minami, Nathaniel K.,Gibson, Tony S.,Anderson, Susanne M.,Bradbury, Annette E.,Nolan, Thomas G.,Semple, J. Edward
-
p. 1203 - 1208
(2007/10/03)
-
- Thrombin inhibitors, the preparation and use thereof
-
Compounds of the formula and the salts thereof with physiologically tolerated acids and the stereoisomers thereof, in which the substituents have the meanings stated in the description, are described. Also disclosed are intermediates for their preparation. The compounds are suitable for controlling diseases.
- -
-
-
- A novel series of selective leukotriene antagonists: Exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles
-
A systematic structure-activity exploration of the carboxylic acid region in a series of indole- or indazole-derived leukotriene antagonists 1 led to several discoveries. Use of the 3-methoxy-p-tolyl fragment (illustrated in acid 1) for connecting the indole and the acidic site provides the most potent carboxylic acids 1, tetrazoles 20, and aryl sulfonimides 21. The aryl sulfonimides are 5-500 times more potent (in vitro and/or in vivo) than the corresponding carboxylic acids 1. The o-tolyl sulfonimides such as 114 show greater oral potency than the phenyl sulfonimides at a given level of in vitro activity. Acidic keto sulfone derivatives 10 (Nu = CH(CO2CH3)SO2Ph) mimic the activity of the sulfonimides.
- Yee,Bernstein,Adams,Brown,Cronk,Hebbel,Vacek,Krell,Snyder
-
p. 2437 - 2451
(2007/10/02)
-
- Heterocyclic amide derivatives and pharmaceutical use
-
The invention concerns novel, pharmaceutically useful, amide derivatives of certain benzoheterocyclylalkanoic acids (and related tetrazoles and acylsulphonamides) of the formula I and salts thereof, wherein the radicals R1, R2, L, X, Y, Z, A1, Q, A2 and M have the meanings set out in the specification. The invention also includes pharmaceutical compositions incorporating a formula I compound or a salt thereof, a process for the manufacture of the said compound, together with intermediates for use in the latter process. STR1
- -
-
-
